ALIGN TECHNOLOGY (ALGN) Company Report

Align Technology will launch the Zero by Three no-refinement, three-year aligner product suite broadly in North America in Q1 2026, followed by phased rollouts in Europe and APEC, offering doctors tiered pricing and the option to purchase refinements at $180 each in the U.S.
CFO John Morici expects a 1%–2% ASP headwind in the near term from country and product mix shifts, offset by a targeted 100 bp operating margin improvement in 2026 driven by portfolio evolution and recent restructuring
Partnerships with DSOs are delivering double-digit North American growth by emphasizing active patient conversion, digital treatment planning, financing solutions, and leveraging the DSP subscription program for aligners
The company plans to initiate direct fabrication in 2026 with printed retainers using proprietary high-viscosity resin on Cubicure printers, progressing to more complex aligner products in 2027 to realize material and labor efficiencies

2 days ago

Transcript

Align Technology outlines product and manufacturing strategy at HealthCONx conference

ALGN

Product Launch

Guidance Update

Zero by Three product suite introduced, offering a 3-year no-refinement aligner option alongside existing 3- and 5-year plans, enhancing customer choice and aligning deferred revenue accounting across products.
ASPs projected to decrease 1–2% in the near term due to country and product mix shifts and tiered discounts, while expecting 100 bps gross margin improvement and overall op-margin leverage from product evolution and restructuring.
Adoption of an active patient engagement model in the U.S.—including intraoral scanning, treatment simulation, targeted financing under $100/month, and localized marketing—has driven double-digit growth in DSO volume.
Align is positioned in China with end-to-end local operations to navigate evolving Value-Based Purchasing policies, viewing potential cost convergence between clear aligners and wires/brackets as an opportunity to expand its 15% aligner share.
Direct-fabrication roadmap targets a retainer launch in 2026, using proprietary high-viscosity bio-sourced resin and Cubicure printers, progressing toward mass production of customized aligners with improved material and labor efficiency.

2 days ago

Transcript

Align Technology details product launches and strategic priorities at HealthCONx Conference

ALGN

Product Launch

Align to launch Zero by Three, a no-refinement, three-year aligner product in North America in 1Q26, with Europe and APEC rollouts later in the year; refinements priced at $180 per case in the U.S.
ASP expected to decline 1–2% in the near term due to country and product mix, while targeting a 100 bp operating-margin improvement in 2026 through gross-margin gains and cost restructuring
U.S. DSO channels experienced double-digit volume growth in 2025, driven by active patient conversion strategies and enhanced doctor support programs
Direct-fabrication roadmap uses a bio-sourced, high-viscosity resin and the Cubicure platform, with the first 3D-printed retainer launching in 2026 and scale-up to complex aligners by 2027

2 days ago

Transcript

Align Technology CFO outlines growth strategy at Piper Sandler Conference

ALGN

Product Launch

New Projects/Investments

CFO John Morici noted US consumer demand remains stable, underpinning active conversion efforts through DSOs and targeted marketing to drive Invisalign case volumes.
Over 50% of Align’s revenues come from underpenetrated international markets—including India, Southeast Asia and Eastern Europe—which are delivering strong double-digit growth via digital orthodontic adoption and DSO partnerships.
In China, with <15% clear aligner penetration versus 85% wires/brackets, anticipated VBP reforms may narrow the price gap and accelerate clear aligner conversions, leveraging Align’s local manufacturing footprint.
The company is expanding its portfolio with zero-refinement and tiered service options to give doctors pricing and treatment flexibility, rolling out broadly in North America in Q1 2026.
Align’s direct-fabrication scale-up continues: retainers launch mid-2026, followed by more complex appliance production and full aligner manufacturing in 2027.

3 days ago

Transcript

Align Technology provides growth outlook and product roadmap

ALGN

Guidance Update

Product Launch

New Projects/Investments

U.S. consumer demand for Invisalign remains stable, with dental service organizations driving active conversion through scanning, visualization, pricing and financing support.
International markets are under-penetrated, delivering double-digit growth in regions like Southeast Asia, Latin America, Eastern Europe, India and Turkey.
In China, clear aligners account for <15% of treatments (85% private-pay), and upcoming value-based pricing (VBP) is expected to narrow the cost gap with brackets and potentially boost aligner utilization.
Average selling prices for Invisalign are projected to decline 1–2% annually, driven by geographic and product mix rather than like-for-like discounting.
Portfolio evolution includes rolling out a zero-refinement three-year product to more doctors in Q1 2026 and launching direct fabrication of retainers mid-2026, with full aligner scale-up targeted for 2027.

3 days ago

Transcript

Align Technology details growth strategy at Piper Sandler conference

ALGN

New Projects/Investments

John Morici states US Invisalign demand remains stable, with dental service organizations (DSOs) driving active patient conversion through scanning, visualization, pricing, and financing.
Adoption of new teen-focused products (IPE, palate expanders, mandibular advancement) and the DSP touch-up subscription program are boosting volume and offering higher gross margins.
International markets remain largely underpenetrated, fueling double-digit growth in regions like India, Southeast Asia, Latin America, and Eastern Europe; China’s private-pay model and local manufacturing position Align to navigate upcoming VBP reforms.
Align is rolling out limited- and no-refinement product options globally (zero refinements in North America from Q1 2026) to give doctors treatment choice, while piloting direct fabrication of retainers mid-2026 and scaling to aligners by 2027.

3 days ago

Transcript

Align Technology outlines strategic growth drivers at Jefferies London Healthcare Conference 2025

ALGN

Product Launch

Share Buyback

New Projects/Investments

Align underscores its 30-year leadership in clear aligners, with a global manufacturing footprint in China, Poland and Mexico and advanced technologies (IPE, mandibular advancement, 3D printing) enabling coverage of 100% of orthodontic cases.
U.S. retail remains sluggish, driving greater emphasis on DSOs (~25% of volume) and “active conversion” through financing, discounts and targeted downstream marketing in key zip codes to accelerate growth.
Launched lower upfront-cost product tiers (e.g., 3 years/3 refinements or no-refinement models), supporting a 1.6 average refinements per case, boosting utilization, price elasticity and ASP/gross-margin benefits.
Targets 100 bp of operating-margin expansion in 2026—split roughly 50/50 between product-mix/COGS efficiencies (regional manufacturing, freight savings) and OpEx levers—while scaling DirectFab 3D printing, with resin supply and Cubicure process validated and first retainer trials in Q1 2026.
Plans ~$100 m in 2025 CapEx for facility upgrades and has earmarked all U.S. cash for share buybacks (∼$200 m by Jan 2026), with no planned acquisitions beyond core orthodontic/restorative offerings.

Nov 18, 2025, 10:30 AM

Transcript

Align Technology outlines growth strategies and market trends at UBS Global Healthcare Conference 2025

ALGN

Align sold to a record 88,000 doctors globally, spanning orthodontists and GPs, and aims to boost utilization via expanded digital scanner deployment and local marketing initiatives.
The installed iTero base exceeds 100,000 scanners, with 90% of doctors equipped and multi-scanner practices driving ~4× higher Invisalign volume through frequent patient scans.
New offerings, including the palatal expander and mandibular advancement with occlusal blocks, supported an 8% YoY rise in teen treatment in Q3, enhancing portfolio breadth and gross margin.
Nine of the top 10 markets achieved year-over-year order growth in Q3—led by EMEA, APAC, and LATAM—while U.S. growth relies on active conversion tactics among retail and DSO-affiliated practices.
Emphasis on “active” go-to-market (local marketing, patient financing, treatment planning), with DSOs seeing double-digit growth, underpinning a 5–15% volume growth target.

Nov 11, 2025, 4:45 PM

Transcript

Align Technology reports Q3 2025 results

ALGN

Earnings

Revenue: Q3 total revenues of $995.7 M, up 1.8% YoY and down 1.7% QoQ; clear aligner revenues $805.8 M (+2.4% YoY) and systems & services $189.9 M (-0.6% YoY)
Profitability: Q3 non-GAAP operating margin at 23.9%, exceeding the outlook of ~22%
Volume growth: Clear aligner cases reached 648,000, up ~5% YoY, driven by EMEA, APAC, and LatAm; North American retail channels remained mixed with strong DSO growth
Innovation: Launched ClinCheck Live Plan, automating initial treatment plans in 15 minutes, and expanded iTero Lumina and exocad ART pilots to enhance digital workflows

Oct 29, 2025, 8:30 PM

Transcript

Align Technology reports Q3 2025 results

ALGN

Earnings

Guidance Update

Share Buyback

Align reported Q3 revenues of $995.7 M, up 1.8% YoY and down 1.7% QoQ, with a non-GAAP operating margin of 23.9%.
Q3 clear aligner revenues were $805.8 M (+2.4% YoY) on 648 K cases (+5% YoY), while imaging systems & services revenues were $189.9 M (-0.6% YoY, -8.6% QoQ).
The company repurchased 0.5 M shares at an average price of $136.77, leaving $928.4 M available under its April 2025 buyback program.
Q4 2025 guidance: revenues of $1.025 B–$1.045 B; GAAP gross margin 65.5%–66%; non-GAAP gross margin ~71%; non-GAAP operating margin ~26%; fiscal 2025 clear aligner volume growth mid-single digits, revenue flat to slightly up YoY.

Oct 29, 2025, 8:30 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for ALIGN TECHNOLOGY.

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What did Joseph M. Hogan say about margins?What are ALIGN TECHNOLOGY's strategic priorities?How is ALIGN TECHNOLOGY positioned vs competitors?How did ALIGN TECHNOLOGY do last quarter?

Let Fintool AI Agent track ALIGN TECHNOLOGY's earnings for you

Get instant analysis when filings drop